Mr. Dey co-founded Bluejay Diagnostics in 2015, after co-founding Lana Management & Business Research International (LMBRI) in 2007. LMBRI is a management consulting company focused on the launch and marketing of medical products in the US, Japan and EU.
Mr. Dey spent about eight years at LMBRI, consulting with companies such as Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), and Fuji Chemicals. Prior to this, he held executive positions at several firms. From 2005–07, he was Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca). From 2001–05, he was Head of Business Development, Western US, at IMPATH, Inc. Here, he handled three business units and the introduction of a new product, Her2neu Diagnostics, for the treatment of breast cancer, with Herceptin. He was also Chief Business Officer at Genmethrax, Inc; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis).
Mr. Dey is a Bachelor of Science and has a master’s degree in Biochemistry from Visva-Bharati University in India and PhD in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also holds a Master of Business Administration degree (Fulbright Scholarship) from the University of Cambridge.
Mr. Dey co-founded Bluejay Diagnostics in 2015, after co-founding Lana Management & Business Research International (LMBRI) in 2007. LMBRI is a management consulting company focused on the launch and marketing of medical products in the US, Japan and EU.
Mr. Dey spent about eight years at LMBRI, consulting with companies such as Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), and Fuji Chemicals. Prior to this, he held executive positions at several firms. From 2005–07, he was Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca). From 2001–05, he was Head of Business Development, Western US, at IMPATH, Inc. Here, he handled three business units and the introduction of a new product, Her2neu Diagnostics, for the treatment of breast cancer, with Herceptin. He was also Chief Business Officer at Genmethrax, Inc; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis).
Mr. Dey is a Bachelor of Science and has a master’s degree in Biochemistry from Visva-Bharati University in India and PhD in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also holds a Master of Business Administration degree (Fulbright Scholarship) from the University of Cambridge.
Mr. Fisher joined Bluejay in 2022. Prior to this, from 2010 to 2021, he was Executive Vice President, Chief Financial Officer and Treasurer of Meridian Bancorp, Inc., a $6.6 billion NASDAQ-listed financial institution, and its subsidiary, East Boston Savings Bank (merged with Rockland Trust in November 2021). Prior to that, he served as Vice President and Treasurer at Beverly National Bank and as a senior auditor at Parent, McLaughlin & Nangle, CPAs (now Marcum LLP).
Mr. Fisher is a Certified Public Accountant. He received his Bachelor’s Degree in Business Administration from the Isenberg School of Management at the University of Massachusetts at Amherst and is a graduate of the New England School for Financial Studies.
Dr. Cook joined Bluejay in 2021. From 2014–21, he served as Chief Executive Officer at NanoHybrids, Inc., a nanotechnology company focused on developing theranostic nanoparticle platform technologies. Here, he was Director and Chairman of the Board from 2020–21, and Senior Scientist from 2014–17, overseeing the development of several core technologies.
Dr. Cook did his PhD in Biomedical Engineering from The University of Texas at Austin, focusing on the design and development of medical diagnostic systems. His postdoctoral work included improving the bioconjugation strategies of nanoparticles for molecular targeting. Dr. Cook also serves as Ad-hoc Reviewer for numerous panels at the National Institute of Health and peer-reviewed scientific journals.
